Roche's experimental eye drug shows vision improvements in trials
Michael Vi/iStock Editorial via Getty Images
Roche (RHHBY)(RHHBF)(RHHVF) said its experimental eye drug vamikibart helped patients maintain improvements in vision for a full year in two late-stage clinical trials, potentially offering an alternative to steroid treatments that can cause serious side effects.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.